Neurogene — Down 36% — Extends Losses After Side Effect Derails Its Rett Syndrome Drug
Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett syndrome treatment. The post Neurogene — Down 36% — Extends Losses After Side Effect Derails Its Rett Syndrome Drug appeared first on Investor's Business Daily.
Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett syndrome treatment.
The post Neurogene — Down 36% — Extends Losses After Side Effect Derails Its Rett Syndrome Drug appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
